FACBC, Methionine

PreclinicalSmall molecule

MMemorial Sloan Kettering Cancer Center

FACBC, Methionine is one of 7 small molecule programs targeting Brain Tumors. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Brain TumorsCompleted

Brain TumorsPreclinical

Completed

Competition

Competitive Landscape

6 competitors in Brain Tumors

#DrugCompanyPhaseTrials

Keppra

UCB

Phase 3

1 2

Lumakras

Amgen

Phase 1

1 3

Triostat

VViking Therapeutics, Inc.

Preclinical

1 4

5-Aminolevulinic Acid

DDavid W. Roberts

Phase 1

1 5

Fimepinostat

UUniversity of California, Los Angeles

Phase 1

1 6

FACBC, Methionine

MMemorial Sloan Kettering Cancer Center

Preclinical

1 7

NM404

UUniversity of Wisconsin, Madison

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Brain Tumors1 trial

Imaging Brain Tumors With FACBC and Methionine

Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT00597246·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for FACBC, Methionine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FACBC, Methionine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FACBC, Methionine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMemorial Sloan Kettering Cancer Center

FACBC, Methionine

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Brain Tumors1 trial

References

Drug Info

Quick Facts

Related News